Form 4: Humana CFO Mellet Reports Routine Stock Transactions

Humana's Chief Financial Officer, Celeste Mellet, reported the acquisition of shares and subsequent disposition for tax purposes related to stock vesting.

Summary

• Celeste Mellet, Humana Inc.'s Chief Financial Officer, reported transactions involving Humana Common Stock on December 15, 2025.
• Mellet acquired 2,128 shares of Humana Common Stock at a price of $0, likely due to the vesting of equity awards.
• On the same date, Mellet disposed of 1,222 shares at a price of $270.155 per share to cover tax liabilities associated with the vesting shares.
• Following these transactions, Mellet beneficially owns 28,454 shares of Humana Common Stock.
• The beneficial ownership includes 27,548 restricted stock units (RSUs) representing a contingent right to receive common stock under the company's 2019 Amended & Restated Plan.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The transaction is routine for executive compensation, indicating continued alignment of management interests with shareholders through equity vesting. The disposition for tax purposes is standard practice.

Positives

• The acquisition of 2,128 shares indicates the vesting of equity awards, which is a common form of executive compensation and aligns management's interests with shareholders.

Negatives

• The disposition of 1,222 shares for tax purposes reduces the direct shareholding of the CFO, though this is a standard practice for covering tax obligations on vested equity.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The vesting of equity awards aligns the CFO's interests with shareholder value creation. The tax-related sale is a common practice and generally has minimal impact on overall share price.

Key Dates

Recommendation

The Form 4 filing details a routine insider transaction involving the vesting of equity awards and the subsequent sale of shares to cover tax obligations. This is a standard practice for executive compensation and does not provide new fundamental information to alter an investment thesis. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

Humana, HUM, Celeste Mellet, CFO, Form 4, Insider Trading, Stock Transaction, Equity Vesting, Restricted Stock Units, Executive Compensation